Metabolic control by insulin detemir in basal-bolus therapy: Treat-to-target study in children and adolescents with type 1 diabetes

Pediatric Diabetes

Volumn 14, Issue 3, 2013, Pages 196-202

  Nimri, Revital ^a   Lebenthal, Yael ^a   Shalitin, Shlomit ^a,b   Benzaquen, Hadasa ^a   Demol, Sharon ^a   Phillip, Moshe ^a,b  

^a SCHNEIDER CHILDREN S MEDICAL CENTER OF ISRAEL   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

Basal insulin analog; Basal bolus intensive therapy; Once twice daily; Pediatric

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; INSULIN ASPART; INSULIN DETEMIR; ISOPHANE INSULIN;

ADOLESCENT; ADULT; ARTICLE; BLOOD GLUCOSE METER; BLOOD GLUCOSE MONITORING; BODY MASS; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DISEASE DURATION; DOSAGE SCHEDULE COMPARISON; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; MALE; METABOLIC REGULATION; OPTIMAL DRUG DOSE; PATIENT SATISFACTION; PRESCHOOL CHILD; PRIORITY JOURNAL; PROSPECTIVE STUDY; PUBERTY; SCHOOL CHILD;

ADOLESCENT; ALGORITHMS; CHILD; COHORT STUDIES; DIABETES MELLITUS, TYPE 1; DRUG ADMINISTRATION SCHEDULE; DRUG MONITORING; DRUG THERAPY, COMBINATION; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INCIDENCE; INSULIN ASPART; INSULIN, LONG-ACTING; ISRAEL; MALE;

EID: 84876789278     PISSN: 1399543X     EISSN: 13995448     Source Type: Journal    
DOI: 10.1111/pedi.12012     Document Type: Article

References (23)

1. Kapellen TM, Wolf J, Rosenbauer J et al. Changes in the use of analogue insulins in 37 206 children and adolescents with type 1 diabetes in 275 German and Austrian centers during the last twelve years. Exp Clin Endocrinol Diabetes 2009: 117: 329-335.
2. Havelund S, Plum A, Ribel U et al. The mechanism of protraction of insulin detemir, a long-acting, acylated analog of human insulin. Pharm Res 2004: 21: 1498-1504.
3. Plank J, Bodenlenz M, Sinner F et al. A double-blind, randomized, dose-response study investigating the pharmacodynamic and pharmacokinetic properties of the long-acting insulin analog detemir. Diabetes Care 2005: 28: 1107-1112.
4. Porcellati F, Rossetti P, Ricci NB, Pampanelli S, Torlone E, Campos SH. Pharmacokinetics and pharmacodynamics of the long-acting insulin analog glargine after 1week of use compared with its first administration in subjects with type 1 diabetes. Diabetes Care 2007: 30: 1261-1263.
5. Heise T, Nosek L, Rønn BB et al. Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes. Diabetes 2004: 53: 1614-1620.
6. Le Floch JP, Lévy M, Mosnier-Pudar H et al. Assessment of Detemir Administration in Progressive Treat-to-Target Trial (ADAPT) Study Group Comparison of once- versus twice-daily administration of insulin detemir, used with mealtime insulin aspart, in basal-bolus therapy for type 1 diabetes: assessment of detemir administration in a progressive treat-to-target trial (ADAPT). Diabetes Care 2009: 32: 32-37.
7. Heller S, Koenen C, Bode B. Comparison of insulin detemir and insulin glargine in a basal-bolus regimen, with insulin aspart as the mealtime insulin, in patients with type 1 diabetes: a 52-week, multinational, randomized, open-label, parallel-group, treat-to-target noninferiority trial. Clin Ther 2009: 31: 2086-2097.
8. Fontaine P, Gin H, Pinget M, Thivolet C, Hanaire H, Robert JJ. Effect of insulin detemir dose frequency on clinical outcomes in patients with diabetes in PREDICTIVE. Adv Ther 2009: 26: 535-551.
9. Danne T, Lüpke K, Walte K, Von Schuetz W, Gall MA. Insulin detemir is characterized by a consistent pharmacokinetic profile across age-groups in children, adolescents, and adults with type 1 diabetes. Diabetes Care 2003: 26: 3087-3092.
10. Danne T, Datz N, Endahl L et al. Insulin Detemir is characterized by a more reproducible pharmacokinetic profile than insulin glargine in children and adolescents with type 1 diabetes: results from a randomized, double-blind, controlled trial. Pediatr Diabetes 2008: 9: 554-560.
11. Robertson KJ, Schoenle E, Gucev Z, Mordhorst L, Gall MA, Ludvigsson J. Insulin detemir compared with NPH insulin in children and adolescents with Type 1 diabetes. Diabet Med 2007: 24: 27-34.
12. Thalange N, Bereket A, Larsen J, Hiort LC, Peterkova V. Treatment with insulin detemir or NPH insulin in children aged 2-5yr with type 1 diabetes mellitus. Pediatr Diabetes 2011: 21: 632-641.
13. Braun D, Konrad D, Lang-Muritano M, Schoenle E. Improved glycemic control and lower frequency of severe hypoglycemia with insulin detemir; long-term experience in 105 children and adolescents with type 1 diabetes. Pediatr Diabetes 2008: 9: 382-387.
14. Dündar BN, Dündar N, Eren E. Comparison of the efficacy and safety of insulin glargine and insulin detemir with NPH insulin in children and adolescents with type 1 diabetes mellitus receiving intensive insulin therapy. J Clin Res Pediatr Endocrinol 2009: 1: 181-187.
15. Kurtoglu S, Atabek ME, Dizdarer C, Pirgon O, Isguven P, Emek S. PREDICTIVE Turkey Study Group Insulin detemir improves glycemic control and reduces hypoglycemia in children with type 1 diabetes: findings from the Turkish cohort of the PREDICTIVE observational study. Pediatr Diabetes 2009: 10: 401-407.
16. American Diabetes Association. Standards of medical care in diabetes. Diabetes Care 2005; 28 (Suppl. 1):S4-S36.
17. American Diabetes Association. Standards of medical care in diabetes-2011. Diabetes Care 2011: 34 (Suppl. 1): S11-S61.
18. Marshall WA, Tanner JM. Variations in the pattern of pubertal changes in boys. Arch Dis Child 1970: 45: 13-23.
19. Marshall WA, Tanner JM. Variation in the pattern of pubertal changes in girls. Arch Dis Child 1969: 49: 291-303.
20. Bradley C. The diabetes treatment satisfaction questionnaire. In: Bradley C, ed. Handbook of Psychology and Diabetes: A Guide to Psychological Measurement in Diabetes Research and Practice. Chur: Harwood Academic Publishers, 1994: 111-132.
21. Szadkowska A, Pietrzak I, Mianowska B et al. Insulin sensitivity in Type 1 diabetic children and adolescents. Diabet Med 2008: 25: 282-288.
22. Davis E, Keating B, Byrne G, Russell M, Jones T. Hypoglycemia: incidence and clinical predictors in a large population-based sample of children and adolescents with IDDM. Diabetes Care 1997: 20: 22-25.
23. Ashwell SG, Gebbie J, Home PD. Twice-daily compared with once-daily insulin glargine in people with Type 1 diabetes using meal-time insulin aspart. Diabet Med 2006: 23: 879-886.